Heron D, Saiful M, Herman JM, Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy (SBRT) 2019, p3-5, DemosMedical
Amin SA, Alam M, Baine MJ, et al. The impact of stereotactic body radiation therapy on the overall survival of patients diagnosed with early-stage non-small cell lung cancer. Radiother Oncol. 2021;155:254-260.
DOI: 10.1016/j.radonc.2020.10.028
Timmerman RD, Hu C, Michalski JM, et al. Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4(9):1287-1288.
DOI: 10.1001/jamaoncol.2018.1258
Videtic GM, Paulus R, Singh AK, et al. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019;103(5):1077-1084.
DOI: 10.1016/j.ijrobp.2018.11.051
Swaminath, S. Parpia, M. Wierzbicki, V. Kundapur, S.L. Faria. LUSTRE: A Phase III Randomized Trial of Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Hypofractionated Radiotherapy (CRT) for Medically Inoperable Stage I Non-Small Cell Lung Cancer (NSCLC), Int J Radiat Oncol Biol2022. 114(5), 1061-1062,ISSN 0360-3016.
DOI: 10.1016/j.ijrobp.2022.09.009
Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20(4):494-503.
DOI: 10.1016/S1470-2045(18)30896-9
Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials [published correction appears in Lancet Oncol. 2015 Sep;16(9):e427]. Lancet Oncol. 2015;16(6):630-637.
DOI: 10.1016/S1470-2045(15)70168-3
Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22(10):1448-1457.
DOI: 10.1016/S1470-2045(21)00401-0
Chen, H., Laba, J. M., Boldt, R. G., Goodman, C. D., Palma, D. A., Senan, S., & Louie, A. V. (Stereotactic ablative radiation therapy versus surgery in early lung cancer: a meta-analysis of propensity score studies. International J Radiat Oncol Phys, 2018;101(1), 186-194.
DOI: 10.1016/j.ijrobp.2018.01.064
Bartl AJ, Mahoney M, Hennon MW, et al. Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done. Cancers (Basel). 2022;14(3):790. Published 2022 Feb 3.
DOI: 10.3390/cancers14030790
Rodríguez De Dios N, Navarro-Martin A, Cigarral C, Chicas-Sett R, García R, Garcia V, Gonzalez JA, Gonzalo S, Murcia-Mejía M, Robaina R, Sotoca A, Vallejo C, Valtueña G, Couñago F. GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer. World J Clin Oncol 2022; 13(4): 237-266 URL:
DOI: 10.5306/wjco.v13.i4.237
Sebastian NT, Xu-Welliver M, Williams TM. Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances. J Thorac Dis. 2018;10(Suppl 21):S2451-S2464.
DOI: 10.21037/jtd.2018.04.52
Xiao Y, Papiez L, Paulus R, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;73(4):1235-1242.
DOI: 10.1016/j.ijrobp.2008.11.019
Bezjak A, Paulus R, Gaspar LE, et al. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol. 2019;37(15):1316-1325.
DOI: 10.1200/JCO.18.00622
Lindberg K, Grozman V, Karlsson K, et al. The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. J Thorac Oncol. 2021;16(7):1200-1210.
DOI: 10.1016/j.jtho.2021.03.019
Regnery S, Ristau J, Weykamp F, et al. Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3). Radiat Oncol. 2022;17(1):102. Published 2022 May 25.
DOI: 10.1186/s13014-022-02070-x
Guckenberger M, Belka C, Bezjak A, et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiother Oncol. 2020;146:223-229.
DOI: 10.1016/j.radonc.2020.04.001
Widder J, Postmus D, Ubbels JF, Wiegman EM, Langendijk JA. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):e291-e297.
DOI: 10.1016/j.ijrobp.2011.03.052
Wolff HB, Alberts L, Kastelijn EA, et al. Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13(5):689-698.
DOI: 10.1016/j.jtho.2018.01.021
Nestle U, Adebahr S, Kaier K, et al. Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. Radiother Oncol. 2020;148:82-88.
DOI: 10.1016/j.radonc.2020.03.018
Iovoli AJ, Yu B, Ma SJ, Farrugia MK, Dexter EU, Yendamuri S, Bouchard EG, Singh AK. Quality of Life After Stereotactic Body Radiation Therapy or Surgery for Early-Stage NSCLC: A Systematic Review. JTO Clin Res Rep. 2022 Sep 22;3(11):100417.
DOI: 10.1016/j.jtocrr.2022.100417
Palma DA, Nguyen TK, Louie AV, et al. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019;5(5):681–688.
DOI: 10.1001/jamaoncol.2018.6993
Altorki NK, McGraw TE, Borczuk AC, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 2021;22(6):824-835.
DOI: 10.1016/S1470-2045(21)00149-2
Perez CA, Stanley K, Rubin P, Kramer S, Brady L, Perez-Tamayo R, Brown GS, Concannon J, Rotman M, Seydel HG. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer. 1980 Jun 1;45(11):2744-53.
DOI: 10.1002/1097-0142(19800601)45:11<2744::AID-CNCR2820451108>3.0.CO;2-U
M. Pless, R. Stupp, H. Ris, R.A. Stahel, W. Weder, S. Thierstein et al. FINAL RESULTS OF THE SAKK 16/00 TRIAL: A RANDOMIZED PHASE III TRIAL COMPARING NEOADJUVANT CHEMORADIATION TO CHEMOTHERAPY ALONE IN STAGE IIIA/N2 NON-SMALL CELL LUNG CANCER (NSCLC) Annals of Oncology 25 (Supplement 4): iv417–iv425, 2014
DOI: 10.1093/annonc/mdu348.1
Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, Welter S, Budach W, Spengler W, Kimmich M, Fischer B, Schmidberger H, De Ruysscher D, Belka C, Cordes S, Hepp R, Lütke-Brintrup D, Lehmann N, Schuler M, Jöckel KH, Stamatis G, Stuschke M. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015 Dec 10;33(35):4194-201.
DOI: 10.1200/JCO.2015.62.6812
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery. (s/f). Clinicaltrials.gov. Recuperado el 11 de junio de 2023, de https://clinicaltrials.gov/ct2/show/study/NCT03433469
NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations. - Full Text View - Clinicaltrials.gov. (s/f). Clinicaltrials.gov. Recuperado el 11 de junio de 2023, de https://clinicaltrials.gov/ct2/show/NCT02347839
Myall NJ, Das M. Advances in the Treatment of Stage III Non-Small Cell Lung Cancer. Clin Chest Med. 2020 Jun;41(2):211-222.
DOI: 10.1016/j.ccm.2020.02.008
Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352: 257-263 [PMID: 9690404]
DOI: 10.1016/S0140-6736(98)06341-7
Harling L, Jayakumar S, Ashrafian H, Bille A, Toufektzian L, Smith D. Mediastinal Radiotherapy after Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer with N2 Lymphadenopathy: A Novel Meta-Analysis. JTCVS Open 2021; 5: 121-130 [
DOI: 10.1016/j.xjon.2020.12.006
Le Pechoux C, Pourel N, Barlesi F, Faivre-Finn C, Lerouge D, Zalcman G, Antoni D, Lamezec B, Nestle U, Boisselier P, Thillays F, Paumier A, Dansin E, Peignaux K, Madelaine J, Pichon E, Larrouy A, Riesterer O, Lavole A, Bardet A. LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end- point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683. Ann Oncol 2020; 31: S1178 [
DOI: 10.1016/j.annonc.2020.08.2280
Hui Z, Men Y, Hu C, Kang J, Sun X, Bi N, Zhou Z, Liang J, Lv J, Feng Q, Xiao Z, Chen D, Wang Y, Li J, Wang J, Gao S, Wang L, He J. Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial. JAMA Oncol 2021; 7: 1178-1185 [PMID: 34165501
DOI: 10.1001/jamaoncol.2021.1910
Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181-2190.
DOI: 10.1200/JCO.2009.26.2543
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929.
DOI: 10.1056/NEJMoa1709937
Zhao J, Xia Y, Kaminski J, et al. Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies. PLoS One. 2016;11(6):e0157455. Published 2016 Jun 14.
DOI: 10.1371/journal.pone.0157455
Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 [published correction appears in J Natl Cancer Inst. 2012 Jan 4;104(1):79]. J Natl Cancer Inst. 2011;103(19):1452-1460.
De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol. 2009;20(1):98-102.
DOI: 10.1093/annonc/mdn559
Pallis AG, Gridelli C, Wedding U, et al. Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol. 2014;25(7):1270-1283.
DOI: 10.1093/annonc/mdu022
Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e314S-e340S.
DOI: 10.1378/chest.12-2360
Daly ME, Singh N, Ismaila N, et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline [published online ahead of print, 2021 Dec 22]. J Clin Oncol. 2021;JCO2102528.
Atagi S, Mizusawa J, Ishikura S, et al. Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301). Clin Lung Cancer. 2018;19(5):e619-e627.
DOI: 10.1016/j.cllc.2018.04.018
El Sharouni SY, Kal HB, Battermann JJ. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer. 2003;89(12):2184-2189.
DOI: 10.1038/sj.bjc.6601418
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 May;20(5):497-530.
DOI: 10.6004/jnccn.2022.0025
Partridge M, Ramos M, Sardaro A, Brada M. Dose escalation for non-small cell lung cancer: analysis and modelling of published literature. Radiother Oncol 2011; 99: 6-11 [PMID: 21458088
DOI: 10.1016/j.radonc.2011.02.014
Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, Price A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, Koning C; EORTC LCG and RT Group. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer. 2007 Jan;43(1):114-21.
DOI: 10.1016/j.ejca.2006.09.005
Maguire J, Khan I, McMenemin R, O'Rourke N, McNee S, Kelly V, Peedell C, Snee M. SOCCAR: A randomised phase II trial comparing sequential vs concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. Eur J Cancer 2014; 50: 2939-2949 [PMID: 25304298
DOI: 10.1016/j.ejca.2014.07.009
Kaster TS, Yaremko B, Palma DA, Rodrigues GB. Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. Clin Lung Cancer 2015; 16: 71-79 [PMID: 25450876
DOI: 10.1016/j.cllc.2014.08.002
Robinson SD, Tahir BA, Absalom KAR, Lankathilake A, Das T, Lee C, Fisher PM, Bates E, Hatton MQF. Radical accelerated radiotherapy for non-small cell lung cancer (NSCLC): A 5-year retrospective review of two dose fractionation schedules. Radiother Oncol 2020; 143: 37-43 [PMID: 31563408
DOI: 10.1016/j.radonc.2019.08.025
Bradley JD, Hu C, Komaki RR, et al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38(7):706-714.
DOI: 10.1200/JCO.19.01162
Movsas B, Hu C, Sloan J, et al. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. JAMA Oncol. 2016;2(3):359-367.
DOI: 10.1001/jamaoncol.2015.3969
Woodford C, Yartsev S, Dar AR, Bauman G, Van Dyk J. Adaptive radiotherapy planning on decreasing gross tumor volumes as seen on megavoltage computed tomography images. Int J Radiat Oncol Biol Phys. 2007;69(4):1316-1322.
DOI: 10.1016/j.ijrobp.2007.07.2369
Feddock J, Arnold SM, Shelton BJ, et al. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2013;85(5):1325-1331.
DOI: 10.1016/j.ijrobp.2012.11.011
Karam SD, Horne ZD, Hong RL, McRae D, Duhamel D, Nasr NM. Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer. Radiat Oncol. 2013;8:179. Published 2013 Jul 10.
DOI: 10.1186/1748-717X-8-179
Higgins KA, Pillai RN, Chen Z, et al. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. J Thorac Oncol. 2017;12(11):1687-1695.
DOI: 10.1016/j.jtho.2017.07.036
van Elmpt W, De Ruysscher D, van der Salm A, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol. 2012;104(1):67-71.
DOI: 10.1016/j.radonc.2012.03.005
Vera P, Thureau S, Chaumet-Riffaud P, et al. Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by 18F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study). J Nucl Med. 2017;58(7):1045-1053.
DOI: 10.2967/jnumed.116.188367
Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - What limits limited disease? Lung Cancer. 2002 Sep;37(3):271–6.
DOI: 10.1016/S0169-5002(02)00072-7
Small Cell Lung Cancer Guidelines [Internet]. [cited 2023 May 21]. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462
Número de descargas:
37081
Número de visitas:
769
Citas:
0
